Notificação de entrada na fase nacional - PCT
#1.3
09/30/2025
RPI 2856
Application data
Number
112025005888Type
Filing
Publication
PCT
US2023075456 Examination has not been requested yet. Without that request by 09/28/2026, the application is definitively abandoned (art. 33 of the Brazilian IP Act).
Deadline to request examination:09/28/2026(34 days left)
Latest action published by the INPI: 09/30/2025. We update with every new RPI gazette, published weekly.
Applicants
NUVATION BIO INC.
US
Inventors
C. M. (pessoa física)
US
D. H. (pessoa física)
US
I. D. (pessoa física)
US
IPC Classification
Priority claims
US
63/377,511 · 09/28/2022
Abstract
COMPOSTOS ANTICÂNCER DE DIRECIONAMENTO AO RECEPTOR NUCLEAR HORMONAL. A presente invenção refere-se a compostos que compreendem uma carga útil nuclear, tal como um inibidor de topoisomerase, veneno de topoisomerase ou um análogo do mesmo e um epítopo de direcionamento ao receptor nuclear.
Publications in the Brazilian Industrial Property Gazette (RPI).
#1.3
09/30/2025
RPI 2856
#1.1
04/08/2025
RPI 2831
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.